丁忠仁

丁忠仁

丁忠仁(1968～)， 河南淮濱人。復旦大學上海醫學院研究員，博士生導師。

基本介紹

  • 中文名：丁忠仁
  • 出生地：河南淮濱
  • 出生日期：1968
  • 職務：博士生導師
人物經歷,代表論文,

人物經歷

美國血液學會(ASH)、國際血栓與止血學會(ISTH)會員。國家自然科學基金心血管藥理專業同行評議專家。於1990年、1993年和1998年分別從河南醫科大學、中山醫科大學分別獲得醫學學士、碩士和博士學位。
1993年7月 - 1995年8月在廣州白雲山製藥總廠藥物研究所從事抗生素的新藥研發。1998年9月起在北京協和醫院從事”纖溶酶原激活物抑制劑1 （PAI-1）多態性的研究”，2000年8月被評為“副研究員”。2000年8月起在在美國天普大學醫學院Sol Sherry血栓研究中心從事血小板ADP受體的激活機制和以P2Y12受體為靶點的抗血小板藥研究。2007年9月起在復旦大學上海醫學院從事科研、教學工作。主要研究血小板激活的機制、抗血小板藥作用機理和以P2Y12受體為靶點的抗血小板藥的研發。與北京化工大學合作，首次報導了一種同時作用於血小板P2Y12受體和磷酸二酯酶、具有抗血小板活性的全新化合物BF0801。通過對BF0801進行結構改造，得到一種作用機制類似、活性更強的新化合物BF061，其抗血栓活性和氯吡格雷相似（小鼠腸系膜動脈FeCl3損傷血栓模型），但出血副作用更小。BF061的抗血栓作用同時被加拿大McMaster大學證實（小鼠提睪肌動脈雷射損傷血栓模型）。在2011年7月在日本京都舉行的“第23屆國際血栓與止血學會大會” （International Society on Thrombosis and Haemostasis ⅩⅩⅢ Congress，ISTH 2011）上，該課題組抗血小板藥的研究工作同時獲得兩項“青年研究學者獎”（Young Investigator Award)。承擔國家自然科學基金（面上項目）5項、上海市科委“浦江計畫”人才項目1項、科技部和上海市科委新藥創製子課題各1項， 2008年首批首輪入選“上海高校特聘教授”(東方學者)。

代表論文

  1. Hu L, Chang L, Zhang Y, Zhai L, Zhang S, Qi Z, Yan H, Yan Y, Luo X, Zhang S, Wang Y, Kunapuli SP, Ye H, Ding Z*.Platelets Express Activated P2Y12 Receptor in Patients with Diabetes. Circulation 2017; Epub ahead of print (doi: 10.1161/CIRCULATIONAHA.116.026995; IF: 19.3)
  2. Jianqin Ye, Lili Zhai, Shenghui Zhang, Yan Zhang, Leilei Chen, Liang Hu, Si Zhang, Zhongren Ding*. Dl-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase. Platelets 2015; 26(8): 736 - 44 ( IF: 3.2)
  3. Si Zhang, Shenghui Zhang, Liang Hu, Lili Zhai, Ruyi Xue, Jianqin Ye, Leilei, Chen, Jozef S. Mruk, Guanjun Cheng, Satya P. Kunapuli, Zhongren Ding*. Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and ThrombosisIs. Circulation 2015; 131(13): 1160 - 1170 (Featured work with an editorial; IF: 17.2)
  4. Lei Liu, Jian Li, Yan Zhang, Shenghui Zhang, Jianqin Ye, Zhichao Wen, Jianping Ding, Satya P. Kunapuli, Xinping Luo*, Zhongren Ding*. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory. Thromb Res 2014; 134(4): 866 - 76 (IF: 2.45)
  5. SH Zhang, Y Zhang, J Shen, S Zhang, L Chen, J Gu, G Cheng, JS Mruk, L Zhu, SP Kunapuli, Z Ding*. Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signaling and phosphodiesterase. J Thromb Haemost 2013; 11(10): 1855 - 1866 (IF: 5.6)
  6. S Zhang, J Ye, Y Zhang, X Xu, J Liu, SH Zhang, SP Kunapuli, Z Ding*. P2Y12 protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation. J Thromb Haemost 2013; 11(1): 149 -160 (IF: 5.6)
  7. Y Zhang, J Ye, L Hu, S Zhang, SH Zhang, Y Li, SP Kunapuli, Z Ding*. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12 receptor. J Thromb Haemost 2012; 10(10): 2149 - 2157 (IF: 6.1)
  8. Pan C，Wei X*，Ye J，Liu G，Zhang S，Zhang Y，Du H，Ding Z*. BF066, a novel dual target antiplatelet agent without significant bleeding. PloS One 2012; 7: e40451 (IF: 3.7)
  9. Guocheng Liu, Jiaxi Xu, Ning Chen, Si Zhang, Zhongren Ding, Hongguang Du. Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents. Eur J Med Chem 2012; 53: 114 - 123 (IF: 3.5)
  10. Liang Hu, Zhichao Fan, Hongguang Du, Ran Ni, Si Zhang, Kanhua Yin, Jianqin Ye, Yan Zhang, Xunbin Wei, Xiaohui Zhang, Peter L. Gross, Satya P. Kunapuli, Zhongren Ding*. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 2011; 106(6): 1203 - 14 (IF: 5.0)
  11. Guocheng Liu, Jiaxi Xu, Ki Chul Park, Ning Chen, Si Zhang,Zhongren Ding, Feng Wang，Hongguang Du. Novel synthesis approach and antiplatelet-activity evaluation of 6-alkylamino-2,4-dialkyl(aryl)thiopyrimidines. Tetrahedron 2011; 67: 5156 - 5161 (IF: 3.0)
  12. Zhang S, Hu L, Du H, Guo Y, Zhang Y, Niu H, Jin J, Zhang J, Liu J, Zhang X, Kunapuli SP,Ding Z*. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost 2010; 104(4): 845 – 57 (cover figure; IF: 4.7)
  13. Zhongren Ding, Yamini S. Bynagari, Sripal R. Mada, Joseph A Jakubowski, Satya P. Kunapuli. Involvement of extracellular cysteines and oligomeric structures in P2Y12 receptor antagonizing effects of clopidogrel and prasugrel. J Thromb Haemost 2009; 7(1): 232 – 4 (IF: 6.1)
  14. Zhongren Ding, Soochong Kim, Satya P. Kunapuli. Identification of a potent P2Y12 receptor inverse agonist at constitutively active mutant of human P2Y12 receptor. Mol Pharmacol 2006; 69(1): 338 - 345 (IF: 4.5)
  15. Zhongren Ding, Florin Tuluc, Kavita R. Bandivadekan, Lili Zhang, Jianguo Jin, Satya P. Kunapuli. Arg333 and Arg334 in the C-terminus of the human P2Y1 receptor are crucial for Gq coupling. Am J Physiol 2005; 288(3): C559 - 67 (IF: 3.9)
  16. Zhongren Ding*, Jia-Qi Pan. Distribution of PAI-1 promoter 4G/5G polymorphism in Chinese and functional characterization using a luciferase reporter vector. Ann Hematol 2005; 84(3): 183 - 187 (IF: 2.2)
  17. Haripriya Shankar, Swaminathan Murugappan, Jianguo Jin, Soochong Kim，Zhongren Ding, Kevin Wickman, Satya P. Kunapuli. Role of G-protein gated inwardly-rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. Blood 2004; 104(5):1335 - 43 (IF: 9.8)
  18. John Meshki, Florin Tuluc, Ovidiu Bredetean, Zhongren Ding, Satya P. Kunapuli. Molecular mechanism of nucleotide-induced primary granule release in human neutrophils: role for the P2Y(2) receptor. Am J Physiol 2004; 286(2): C264 - 271 (IF: 3.9)
  19. Satya P. Kunapuli, Zhongren Ding, Robert T. Dorsam, Soochong Kim, Swaminathan Murugappan, Todd M. Quiton. ADP receptors-Targets for developing antithrombotic agents. Curr Pharm Design 2003; 9(28): 2303 - 16 (IF: 5.5)
  20. Zhongren Ding, Soochong Kim, Robert T. Dorsam, Jianguo Jin, Satya P. Kunapuli. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, C17 and C270. Blood 2003; 101(10): 3908 - 3914 (IF: 10.1)

相關詞條

熱門詞條

聯絡我們